Amantadine for weight gain associated with olanzapine treatment

Deberdt, Walter; Winokur, Andrew; Cavazzoni, Patrizia; Trzaskoma, Quynh; Carlson, Christopher; Bymaster, Frank P.; Wiener, Karen; Floris, Michel; Breier, Alan

doi:10.1016/j.euroneuro.2004.03.005

Cited by 73 publications

(37 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Weight reduction was reported with open-label add-on treatment of amantadine after 2 weeks in 10 patients taking FGAs (Correa et al 1987). The effect of weight loss could be confirmed by add-on treatment with 100 Á/300 mg/day amantadine for 3Á/6 months in 12 patients who gained excessive weight while taking olanzapine (Floris et al 2001), and in a double-blind, 16-week trial in 60 patients with schizophrenia, schizophreniform or bipolar disorder compared to placebo (Deberdt et al 2005). Amantadine, a dopamine agonist, has a risk of worsening psychosis (Ananth et al 2004).…”

Section: Obesity and Weight Gainmentioning

confidence: 97%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

Section: Obesity and Weight Gainmentioning

confidence: 97%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

show abstract

“…Les résultats des études sont variables. Par exemple, des résultats positifs sont observés pour la nizatidine (Atmaca et al, 2003 ;Atmaca et al, 2004), la reboxetine (Poyurovsky et al, 2003), l'amantadine (Deberdt et al, 2005) et le topiramate (Ko et al, 2005). Par contre, des résultats contradictoires pour la sibutramine (Henderson et al, 2005 ;Weiden et al, 2003) et négatifs pour la famotidine (Poyurovsky et al, 2004) et la fluoxetine (Bustillo et al, 2003 ;Poyurovsky et al, 2002) sont observés.…”

Section: Résumé De L'articleunclassified

Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

Bélanger

Provencher

Shriqui

2013

smq

View full text Add to dashboard Cite

Un gain de poids significatif est associé à l’utilisation des antipsychotiques atypiques, des stabilisateurs de l’humeur et des antidépresseurs employés seuls ou en combinaison. Les personnes avec des troubles psychiatriques sont plus à risque de souffrir d’obésité et du syndrome métabolique que la population générale. Une approche prometteuse pour limiter les conséquences physiques et psychologiques du gain de poids est la modification des habitudes de vie. Nous avons révisé la littérature afin de détailler l’impact de ces programmes sur différentes mesures d’effet. Douze des dix-sept études recensées rapportent un impact significatif de leur programme sur le poids en comparaison des soins usuels généralement offerts aux personnes avec des troubles psychiatriques. L’importance de la mise en place de ces programmes pour les patients psychiatriques en externe est soulignée.Significant weight gain is common in patients with psychiatric disorders taking antipsychotics, mood stabilisers and/or antidepressants. Psychiatric patients are at a higher risk of suffering from obesity and from the metabolic syndrome than the general population. One promising alternative to limiting weight gain involves modifying lifestyle behaviors. We reviewed the literature on behavioral weight management programs for this clientele. Of the 17 identified studies, 12 reported a significant impact of the program on weight gain compared to usual care. The importance of offering weight management programs to psychiatric patients in outpatient settings is stressed

show abstract

“…O efeito da perda de peso foi confirmado por meio de um tratamento de inclusão com 100 a 300 mg/dia de amantadina por 3 a 6 meses em 12 pacientes que ganharam peso excessivamente enquanto recebiam olanzapina (Floris et al, 2001) e numa investigação duplo-cega, com duração de 16 semanas, avaliando 60 pacientes com esquizofrenia, psicose esquizofreniforme ou transtorno bipolar, comparados ao grupo-placebo (Deberdt et al, 2005). A amantadina, um agonista dopaminérgico, pode exacerbar os sintomas psicóticos (Ananth et al, 2004).…”

Section: Obesidade E Ganho De Pesounclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoEstas diretrizes para o tratamento biológico da esquizofrenia foram desenvolvidas pela Força-Tarefa da Federação Mundial das Sociedades de Psiquiatria Biológica (World Federation of Societies of Biological Psychiatry, WFSBP). As metas fixadas durante o desenvolvimento destas diretrizes foi a revisão sistemática de todas as evidências disponíveis referentes ao tratamento da esquizofrenia, tanto no âmbito clínico como no científico, e o estabelecimento de um consenso sobre as principais recomendações para a prática psiquiátrica. Estas diretrizes são destinadas a todos os médicos que atendem e tratam de pacientes portadores de esquizofrenia. Os dados usados para desenvolver estas diretrizes foram extraídos primariamente de vários painéis e diretrizes nacionais para o tratamento da esquizofrenia, assim como de metanálises, revisões e estudos clínicos randomizados sobre a eficácia do tratamento farmacológico e de outras intervenções terapêuticas biológicas, identificadas por uma busca nas bases de dados MedLine e na Biblioteca Cochrane. A literatura identificada

show abstract

Amantadine for weight gain associated with olanzapine treatment

Cited by 73 publications

References 41 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

Contact Info

Product

Resources

About